Pirfenidone slows the development of fibrosis and malignant neoplasms by modulating inflammation in an experimental model of hepatocarcinoma.

Introduction and objectives: Hepatocellular carcinoma (HCC) is the most common liver neoplasm in the world. Inflammatory, oxidative and fibrogenic processes are key in tumor development and propagation. Pirfenidone (PFD) has been shown to have hepatoprotective, anti-fibrogenic and immunomodulatory p...

Full description

Bibliographic Details
Published in:	Annals of Hepatology
Main Authors:	Scarlet Arceo-Orozco, Fernado Caloca-Camarena, Marina Galicia-Moreno, Hugo C. Monroy-Ramírez, Juan Armendáriz-Borunda
Format:	Article
Language:	English
Published:	Elsevier 2024-02-01
Online Access:	http://www.sciencedirect.com/science/article/pii/S1665268124001947

Similar Items

Pirfenidone limits the progression of malignancy and slows the development of fibrosis in experimental hepatocarcinoma.
by: Scarlet Arceo-Orozco, et al.
Published: (2025-04-01)

Pirfenidone induces translocation of sirt1 to nucleus and deacetylation of histone 3 slows down the development of fibrosis and tumorigenicity in a experimental model of hepatocarcinoma.
by: Hugo C. Monroy-Ramírez, et al.
Published: (2024-02-01)

Pirfenidone Reverts Global DNA Hypomethylation, Promoting DNMT1/UHRF/PCNA Coupling Complex in Experimental Hepatocarcinoma
by: Hipolito Otoniel Miranda-Roblero, et al.
Published: (2024-06-01)

Hepatoprotective effects of N-acetylcysteine prevents hepatocellular carcinoma development induced experimentally.
by: Fernando Caloca-Camarena, et al.
Published: (2024-02-01)

Naringin and Naringenin in Liver Health: A Review of Molecular and Epigenetic Mechanisms and Emerging Therapeutic Strategies
by: Roberto Flores-Peña, et al.
Published: (2025-08-01)

Cerium oxide nanoparticles: a promising nanotherapy approach for chronic degenerative diseases
by: Hugo Christian Monroy-Ramirez, et al.
Published: (2025-05-01)

P- 43 PIRFENIDONE PREVENTS NEOPLASTIC LESIONS DEVELOPMENT BY OXIDATIVE, FIBROGENIC, ANTIPROLIFERATIVE AND EPIGENETIC MECHANISMS REGULATION IN A MODEL OF CHEMICAL HEPATOCARCINOGENESIS
by: Hipólito Otoniel Miranda-Roblero, et al.
Published: (2023-03-01)

O-24 PIRFENIDONE PREVENTS NEOPLASTIC LESIONS DEVELOPMENT BY OXIDATIVE, FIBROGENIC, ANTIPROLIFERATIVE AND EPIGENETIC MECHANISMS REGULATION IN A MODEL OF CHEMICAL HEPATOCARCINOGENESIS
by: Hipólito Otoniel Miranda-Roblero, et al.
Published: (2023-03-01)

Pirfenidone Protects from UVB-Induced Photodamage in Hairless Mice
by: Yocasta Martinez-Alvarado, et al.
Published: (2023-03-01)

Inhibition of Ureteral Stricture by Pirfenidone-Loaded Nanoparticle-Coated Ureteral Stents with Slow-Release Pirfenidone
by: Jiang Z, et al.
Published: (2022-12-01)

Effect of Pirfenidone on Vascular Proliferation, Inflammation and Fibrosis in an Abdominal Adhesion Rat Model
by: Pinar Solmaz Hasdemir, et al.
Published: (2017-01-01)

Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
by: Alberto Aimo, et al.
Published: (2022-04-01)

Pirfenidone ameliorates MAFLD by improving insulin sensitivity and reducing epididymal fat
by: J. Gutiérrez-Cuevas, et al.
Published: (2022-12-01)

Nopal and Pirfenidone Ameliorate Epididymal Fat Weight and Anthropometric Parameters in a Mouse Obesity Model with Diethylnitrosamine
by: Jorge Gutiérrez-Cuevas, et al.
Published: (2025-04-01)

Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows
by: Maria Chianese, et al.
Published: (2024-05-01)

Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis
by: Takeda Y, et al.
Published: (2014-03-01)

Pirfenidone Is an Agonistic Ligand for PPARα and Improves NASH by Activation of SIRT1/LKB1/pAMPK
by: Ana Sandoval‐Rodriguez, et al.
Published: (2020-03-01)

An application of pirfenidone-loaded, lung-targeted nanoliposomes for treating inflammation and early pulmonary fibrosis in ARDS
by: Sheng Li, et al.
Published: (2024-03-01)

The administration of pirfenidone modifies the expression of JMJD2B in a murine model of NASH
by: JS Rodriguez Sanabria, et al.
Published: (2022-12-01)

A case report of hepatocarcinoma-originated pericardial malignancy
by: Bin Wu, et al.
Published: (2025-09-01)

NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome
by: Anna Michelotti, et al.
Published: (2021-08-01)

Topical Pirfenidone-Loaded Liposomes Ophthalmic Formulation Reduces Haze Development after Corneal Alkali Burn in Mice
by: Carlos Daniel Diaz-Palomera, et al.
Published: (2022-01-01)

WCN24-1335 PIRFENIDONE DOWNREGULATES RENAL FIBROGENESIS AND INFLAMMATION SLOWING CKD PROGRESSION IN AN EXPERIMENTAL MODEL OF HYPERTENSIVE NEPHROSCLEROSIS
by: ANA LAURA RUBIO FRANCINI, et al.
Published: (2024-04-01)

Metformin enhanced the effect of pirfenidone on pulmonary fibrosis in mice
by: Nana Liu, et al.
Published: (2024-01-01)

Could Pirfenidone Also be Effective in Treating Intestinal Fibrosis?
by: Giovanni Latella, et al.
Published: (2020-07-01)

P-26 EPIGENETIC MARKS IN PATIENTS WITH SUSTAINED VIRAL RESPONSE TO HCV AND RESIDUAL LIVER FIBROSIS ARE RESTORED BY PROLONGED-RELEASE PIRFENIDONE
by: Eira Cerda Reyes, et al.
Published: (2024-12-01)

H3K9me3 demethylation by JMJD2B is regulated by pirfenidone resulting in improved NASH
by: J. Samael Rodriguez-Sanabria, et al.
Published: (2024-10-01)

Genetic variations in idiopathic pulmonary fibrosis and patient response to pirfenidone
by: Aahd Kubbara, et al.
Published: (2023-08-01)

The safety and tolerability of pirfenidone in Indian patients with idiopathic pulmonary fibrosis
by: Avinash Anil Nair, et al.
Published: (2022-01-01)

Pirfenidone decreases insulin, glucagon, leptin, plasminogen activator inhibitor 1, preventing nonalcoholic steatohepatitis and myocarditis in an obesity moldel
by: Daniel López-Cifuentes, et al.
Published: (2024-02-01)

Effects of Pirfenidone and Nintedanib on Markers of Systemic Oxidative Stress and Inflammation in Patients with Idiopathic Pulmonary Fibrosis: A Preliminary Report
by: Alessandro G. Fois, et al.
Published: (2020-10-01)

Pirfenidone in Skin Fibrosis and Scarring: From Bench Insights to Clinical Data
by: Kelson Knighton, et al.
Published: (2025-08-01)

Pirfenidone combined with UC-MSCs reversed bleomycin-induced pulmonary fibrosis
by: Jingran Xu, et al.
Published: (2025-08-01)

Pirfenidone for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
by: Carlos Aravena, et al.
Published: (2015-01-01)

Prolonged release pirfenidone restores miRNA expression and CpG island methylation in patients with HCV sustained virological response and residual liver fibrosis
by: Eira Cerda-Reyes, et al.
Published: (2025-04-01)

Editorial: Community series - liver fibrosis and MAFLD: from molecular aspects to novel pharmacological strategies, volume II
by: Ana Sandoval-Rodriguez, et al.
Published: (2024-02-01)

HCV patients with residual fibrosis after DAA treatment re-establish their epigenetic signature after prolonged-release pirfenidone: MINERVA study
by: Eira Cerda-Reyes, et al.
Published: (2025-10-01)

Hepatocarcinoma invadiendo estómago
by: A. Guzmán-Lepe, et al.
Published: (2021-01-01)

P-61 LIVER TRANSPLANTATION IN HEPATOCARCINOMA: SURVIVAL AND RECURRENCE IN TRANSPLANTED PATIENTS WITH HEPATOCARCINOMA
by: Daniela García, et al.
Published: (2021-09-01)

Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration
by: Satoshi Ikeda, MD, PhD, et al.
Published: (2022-06-01)